一分钟看懂
这是一项关于白血病的II 期研究，登记的药物或干预包括Cyclophosphamide；Fludarabine Phosphate；Ibrutinib；Obinutuzumab，当前状态为研究进行中，已停止招募。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cyclophosphamide；Fludarabine Phosphate；Ibrutinib；Obinutuzumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- M D Anderson Cancer Center · Houston
公开的入选条件
- * Patients with a diagnosis of CLL/small lymphocytic lymphoma (SLL), with mutated (\> 2% deviation from germ line) IGHV gene, who meet criteria to initiate first-line treatment per International Workshop on CLL Working Group (IWCLL) 2008 guidelines
- * Patients must not have received prior CLL-directed therapy
- * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
- * Absolute neutrophil count \> 500 uL
- * Platelet count \> 50,000/uL
- * Serum total bilirubin =\< 1.5 x upper limit of normal (ULN) or =\< 3 x ULN for patients with Gilbert's disease
- * Estimated creatinine clearance \>= 30 mL/min (calculated or measured by 24 hour urine collection)
- * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02629809；登记信息更新于 2026-09-16。